Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBK9AM)

Drug Name
PLX-4720 Drug Info
Synonyms PLX 4720; PLX4720 (BRAF inhibitor)
Cross-matching ID
PubChem CID
24180719
ChEBI ID
CHEMBL1230020
CAS Number
CAS 918505-84-7
TTD Drug ID
D0F5JZ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome biogenesis in eukaryotes 2.04 0.00e+0 52/108 (48.15%) NXT1;NOP56;NHP2;...
DNA replication 2.03 0.00e+0 34/36 (94.44%) SSBP1;RNASEH1;POLE2;...
RNA polymerase 1.95 0.00e+0 23/31 (74.19%) POLR2I;POLR3B;POLR2G;...
Pyrimidine metabolism 1.86 9.70e-3 40/56 (71.43%) NT5E;RRM2;CAD;...
Mucin type O-glycan biosynthesis 1.84 1.36e-2 20/36 (55.56%) GALNT7;ST6GALNAC2;GALNT6;...
ECM-receptor interaction 1.81 1.78e-2 80/88 (90.91%) LAMC2;LAMA3;ITGA4;...
Mismatch repair 1.75 3.74e-2 22/23 (95.65%) SSBP1;POLD4;RFC2;...
Tyrosine metabolism -1.60 4.13e-2 30/36 (83.33%) ADH6;AOC2;FAH;...
Fatty acid biosynthesis -1.62 3.53e-2 16/18 (88.89%) ACSL4;ACACA;ACSL1;...
Butanoate metabolism -1.65 2.51e-2 23/28 (82.14%) AACS;ACAT2;HMGCS1
Fatty acid degradation -1.67 2.14e-2 40/43 (93.02%) ALDH2;ALDH9A1;ADH6;...
Collecting duct acid secretion -1.70 1.79e-2 22/27 (81.48%) ATP6V1D;SLC12A7;TCIRG1;...
Mitophagy -1.71 1.57e-2 56/68 (82.35%) ATG9A;EIF2AK3;PINK1;...
Antigen processing and presentation -1.77 1.03e-2 60/78 (76.92%) PSME2;TAPBP;PDIA3;...
PPAR signaling pathway -1.78 1.03e-2 66/74 (89.19%) ACAA1;UBC;CPT1A;...
Ascorbate and aldarate metabolism -1.78 1.03e-2 15/30 (50%) ALDH2;ALDH9A1;UGDH;...
Synthesis and degradation of ketone bodies -1.78 1.08e-2 9/10 (90%) ACAT2;HMGCS1
Proximal tubule bicarbonate reclamation -1.79 9.82e-3 21/23 (91.3%) SLC4A4;CA4;GLS2;...
Arginine biosynthesis -1.81 8.70e-3 17/22 (77.27%) ASL;GLS2;GLUD2;...
Protein processing in endoplasmic reticulum -1.83 8.04e-3 127/171 (74.27%) DERL1;OS9;LMAN2;...
Linoleic acid metabolism -1.86 4.86e-3 21/29 (72.41%) PLA2G2D;CYP2E1;PLA2G5;...
Vibrio cholerae infection -1.88 5.17e-3 44/50 (88%) ATP6V1D;ARF1;PRKACB;...
Complement and coagulation cascades -1.88 5.51e-3 76/85 (89.41%) SERPIND1;CD46;C1S;...
alpha-Linolenic acid metabolism -1.90 4.43e-3 17/25 (68%) PLA2G10;ACAA1;PLA2G2D;...
Porphyrin and chlorophyll metabolism -1.91 3.18e-3 23/43 (53.49%) UGT2B28;ALAS1;UGT2A3;...
Lysosome -1.92 2.58e-3 115/128 (89.84%) NAGPA;CLTCL1;IDS;...
ABC transporters -1.94 2.82e-3 37/45 (82.22%) TAP1;ABCD3;ABCA6;...
Retinol metabolism -1.97 3.10e-3 41/68 (60.29%) ADH1B;CYP2C8;CYP2C18;...
Cholesterol metabolism -1.98 2.30e-3 44/50 (88%) ABCG5;LIPC;LRPAP1;...
Biosynthesis of unsaturated fatty acids -1.99 2.58e-3 21/27 (77.78%) BAAT;ELOVL5;HACD1;...
Pentose and glucuronate interconversions -2.02 1.48e-3 17/34 (50%) UGDH;GUSB;UGT2B28;...
Metabolism of xenobiotics by cytochrome P450 -2.04 1.72e-3 49/77 (63.64%) CYP2E1;ADH1B;ADH1C;...
Bile secretion -2.12 0.00e+0 68/90 (75.56%) ABCG5;SLC4A4;NR0B2;...
Steroid hormone biosynthesis -2.15 0.00e+0 43/61 (70.49%) STS;CYP21A2;HSD17B3;...
Synaptic vesicle cycle -2.16 0.00e+0 63/78 (80.77%) SLC18A2;CLTCL1;ATP6V1D;...
Terpenoid backbone biosynthesis -2.18 0.00e+0 18/22 (81.82%) MVK;MVD;HMGCR;...
Steroid biosynthesis -2.19 0.00e+0 19/20 (95%) EBP;HSD17B7;DHCR7;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293T CVCL_0063 Homo sapiens 0.125uM - 10uM 6H, 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 1.11uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H